U.S. markets close in 5 hours 38 minutes

JanOne Inc. (JAN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
9.43+0.97 (+11.43%)
As of 10:22AM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close8.46
Open8.88
Bid8.80 x 1000
Ask8.89 x 1100
Day's Range8.71 - 9.59
52 Week Range2.01 - 31.83
Volume164,123
Avg. Volume839,158
Market Cap22.639M
Beta (5Y Monthly)2.01
PE Ratio (TTM)N/A
EPS (TTM)-3.95
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • JanOne Announces Definitive Agreement to Sell its Legacy Recycling Business for $25 Million
    PR Newswire

    JanOne Announces Definitive Agreement to Sell its Legacy Recycling Business for $25 Million

    JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced that is has entered into a definitive agreement to sell its legacy recycling subsidiary, ARCA Recycling, to Virland Johnson, JanOne's Chief Financial Officer, for an aggregate purchase price of approximately $25 million. The agreement follows JanOne's previously announced intent to divest its legacy businesses, allowing for a strategic corporate focus on the Company's core life science assets.

  • JanOne Announces Closing of $6.0 Million Common Stock Offering
    PR Newswire

    JanOne Announces Closing of $6.0 Million Common Stock Offering

    JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced the closing of previously announced its securities offering with gross proceeds of $6.0 million. The registered direct offering resulted in the sale by the company of an aggregate of 571,428 shares of common stock to certain institutional investors at a purchase price of $10.50 per share. The company intends to use the net proceeds from the offering for working capital and general corporate purposes, including the planning of clinical trials for JAN101, the company's lead drug candidate.

  • JanOne Prices $6.0 Million Common Stock Offering
    PR Newswire

    JanOne Prices $6.0 Million Common Stock Offering

    JanOne Inc. (NASDAQ: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced it has entered into a securities purchase agreement with institutional investors for the purchase and sale of 571,428 shares of its common stock at a price of $10.50 per share, pursuant to a registered direct offering. The gross proceeds of the offering are expected to be $6.0 million before deducting fees and other estimated offering expenses. The closing of the registered direct offering is expected to take place on or about February 2, 2021, subject to the satisfaction of customary closing conditions.